长春高新：子公司GenSci120注射液临床试验申请获得批准

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of GenSci120 injection, a humanized anti-PD-1 monoclonal antibody for the treatment of rheumatoid arthritis (RA) [1] Company Summary - Jinsai Pharmaceutical's GenSci120 injection is classified as a Class I new drug for therapeutic biological products [1] - The approval marks a significant milestone in the development of GenSci120, which targets rheumatoid arthritis [1]